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Abstract. The present study describes proton beam therapy as 
a clinical option to achieve local control of giant conjunctival 
melanoma in an aged person, instead of orbital exenteration. 
An 80‑year‑old woman with one‑year history of left‑eye injec‑
tion and hemorrhage experienced rapid growth of the ocular 
surface black mass. At the initial visit, a black, elastic hard, 
hemorrhage‑prone, thickened mass in the size of 30x40 mm 
with a presumed wide stalk covered the total area of the lid 
fissure on the left side. Biopsy of the mass demonstrated 
anomalous melanin‑containing cells in fibrin and hemor‑
rhage, which were positive for cocktail‑mix antibodies against 
tyrosinase, melanoma antigen recognized by T cells‑1 and 
human melanoma black‑45, indicative of malignant mela‑
noma. One month after the initial visit, the patient underwent 
proton beam therapy at the total dose of 70.4 Gy (relative 
biological effectiveness) in 32 fractions (~10 min each) in one 
and a half months. One month after the end of proton beam 
therapy, 3.5 months from the initial visit, the patient was found 
by computed tomographic scan to have multiple metastatic 
lesions in bilateral lung fields. With the evidence of absent 
BRAF mutation, the patient underwent intravenous admin‑
istration of pembrolizumab 77.2 mg every three weeks five 
times in total. Then, three months after proton beam therapy, 
ocular surface melanoma almost subsided and the clear cornea 
allowed visualization of the intraocular lens inside the eye. 
In three weeks, spontaneous corneal perforation was plugged 
with iris incarceration. The patient died suddenly of unknown 
cause 7.5 months from the initial visit. The local control of 
giant conjunctival melanoma was achieved by proton beam 
therapy, leading to patient's satisfaction and better quality of 
life. Proton beam therapy, followed by immune checkpoint 
inhibitors, would become the future standard of care for unre‑
sectable giant conjunctival melanoma.
Introduction
Malignant melanoma as a whole is less frequent in Asian 
populations including Japanese population, compared with 
Caucasian populations. In the field of ophthalmology, mela‑
noma can be encountered rarely in uvea (choroid) (1), lacrimal 
sac (2), conjunctiva and eyelid skin (3,4). Among these 
melanomas in ophthalmic practice, conjunctival malignant 
melanoma is relatively frequent in Asian populations and 
Caucasian populations (3,4). However, no standard treatment 
has been established in conjunctival melanoma which is basi‑
cally at very low incidence (5).
In case of cutaneous melanoma, its excision with ample 
margin of the surrounding normal skin is the standard of 
care for local control of malignancy. In contrast, excision of 
conjunctival melanoma with ample normal margin cannot 
be achieved since the conjunctiva of limited width is the 
essential mucosa to maintain the ocular surface and hence, 
the vision. Due to this anatomical limitation, it is difficult to 
excise conjunctival melanoma at the early phase with ample 
margin of the surrounding normal tissue as is the standard of 
care for cutaneous melanoma. At present, local recurrence is 
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a common sequela to the initial excision of conjunctival mela‑
noma. Orbital exenteration is a final surgical option to achieve 
the local control in the advanced stages when conjunctival 
melanoma shows infiltration into the surrounding tissue such 
as the eyelid skin and the sclera of the eyeball. It would be 
disastrous for patients to lose the vision of one eye abruptly by 
the orbital exenteration. Invasive surgery of the orbital exenter‑
ation would also put physical and psychological burdens on the 
aged people who are prone to develop conjunctival melanoma.
In the general belief that melanoma would not respond 
sufficiently to external beam radiation, radiotherapy has 
played a limited role only in adjunct or palliative treat‑
ment for metastatic diseases of cutaneous melanoma (6,7), 
conjunctival melanoma (5) and head and neck mucosal mela‑
noma (8,9). Under the circumstances, proton beam therapy 
has been tried as a treatment option for the local control of 
conjunctival melanoma and has been indeed shown to be 
effective (5,10‑15). In Japan, proton beam therapy for head and 
neck cancer including melanoma (16‑18) has been covered by 
reimbursement from the national health insurance since April 
2018. Within the framework of the national health insurance, 
immune checkpoint inhibitors and molecular target drugs such 
as MEK inhibitors and BRAF inhibitors can be also used in 
the case of unresectable and metastatic malignant melanoma, 
based on the genetic testing of BRAF mutations in melanoma 
tissues (19,20).
The present study dealt with an aged patient who showed 
giant conjunctival melanoma at the initial presentation and 
who decided to choose proton beam therapy as a first‑line 
therapeutic option for the local control. Furthermore, based on 
no BRAF mutation detected in the melanoma tissue, pembro‑
lizumab, PD‑1 immune checkpoint inhibitor (19,20), was 
introduced as a current standard therapy toward metastatic 
lung lesions after the proton beam therapy.
Case report
An 80‑year‑old woman noticed injection and hemorrhage in 
the left eye one year previously and she removed the painless 
ocular surface scab by herself frequently. One month previ‑
ously, the black mass grew out of the lid fissure rapidly and 
she could not close the left eye (Fig. 1A). She visited a local 
hospital and was referred to Okayama University Hospital. At 
the initial visit, the best‑corrected visual acuity was 1.2 in the 
right eye and light perception in the left eye. The intraocular 
pressure in the right eye was 12 mmHg and the optic nerve 
disc had glaucomatous cupping as a cup/disc ratio of 0.9. 
Otherwise, the right eye had nothing notable. She had under‑
gone cataract surgery in the left eye four years previously. She 
had no other medical history and took no medication. A black, 
elastic hard, hemorrhage‑prone, thickened mass in the size of 
30x40 mm with a presumed wide stalk covered the total area 
of the lid fissure on the left side (Fig. 1A) and the mass moved 
slightly with eye movement, indicative of the tumor origin on 
the ocular surface.
Magnetic resonance imaging showed the intact eye ball on 
the left side and no infiltration deeply into the orbit (Fig. 2A). 
Whole‑body 2‑[18F]fluoro‑2‑deoxy‑D‑glucose positron emis‑
sion tomography (FDG‑PET) showed high uptake in the 
eyelid area with the mass on the left side (Fig. 2B, maximum 
standardized uptake value, SUVmax=14.04) and had no 
abnormal uptake in other sites of the body. Surface biopsy 
of the mass and the neutral formalin‑fixed paraffin sections 
demonstrated anomalous melanin‑containing cells in fibrin 
and hemorrhage (Fig. 3A). Immunostaining at the in‑house 
pathology laboratory showed that anomalous cells were 
positive for cocktail‑mix antibodies against tyrosinase, 
melanoma antigen recognized by T cells‑1 and human mela‑
noma black‑45 (Fig. 3B), leading to pathological diagnosis of 
malignant melanoma.
The patient underwent proton beam therapy one month 
after the initial visit, at the total dose of 70.4 Gy (relative 
biological effectiveness) in 32 fractions (~10 min each) 
for one and a half months. One month after the conclu‑
sion of proton beam therapy and three and a half months 
from the initial visit, the patient was found by computed 
tomographic scan to have multiple metastatic lesions in 
bilateral lung fields (Fig. 2C). Excisional biopsy of residual 
melanotic lesions in the upper eyelid skin on the left side 
(Fig. 1B and D) showed melanin‑containing epithelioid 
cells with large nuclei and apparent nucleoli (Fig. 4A and B) 
arranged in alveolar pattern, which confirmed the patho‑
logical diagnosis of malignant melanoma at the in‑house 
Figure 1. The mass before and after proton beam therapy. (A) A black, elastic 
hard, hemorrhage‑prone, thickened mass arising from the ocular surface 
on the left side which prevents the eyelid from closing at the initial visit in 
an 80‑year‑old woman. (B and C) The mass has been reduced 2.5 months 
after the conclusion of proton beam therapy, 5 months from the initial visit 
and (D‑F) has almost subsided in half a month, 5.5 months from the initial 
visit. (F) Note the transparent cornea to visualize inside the eye globe. (G) In 
three weeks, spontaneous corneal perforation has been plugged with iris 
incarceration. 
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pathology laboratory. BRAF mutations (V600E and V600K) 
were tested by real‑time PCR in the DNA sample extracted 
from the neutral formalin‑fixed paraffin sections and were 
shown to be absent at an external diagnostic laboratory 
(LSI Medience Corporation). The patient then, underwent 
intravenous administration of pembrolizumab 77.2 mg every 
three weeks five times in total.
At three months after the conclusion of proton beam 
therapy, five and a half months from the initial visit, ocular 
surface melanoma almost subsided (Fig. 1D and E) and the 
clear cornea allowed visualization of the intraocular lens 
inside the eye (Fig. 1F). In three weeks, spontaneous corneal 
perforation was plugged with iris incarceration (Fig. 1G). 
Around the same time, the patient felt malaise and was found 
to have hypothyroidism which was evidenced by low free T3 at 
1.75 pg/ml, low free T4 at 0.90 ng/dl, high TSH at 39.9 µU/ml, 
high anti‑thyroglobulin antibody (TgAb) at 20,664 IU/ml and 
high anti‑thyroid peroxidase antibody (TPOAb) at 2,580 IU/ml. 
The patient started to take levothyroxine sodium hydrate 
0.25 µg daily. She died suddenly of unknown cause 7.5 months 
from the initial visit.
Discussion
The clinical question in the present study is that proton beam 
therapy might be a treatment option in the standard of care for 
advanced conjunctival malignant melanoma in the era when 
proton beam therapy is included in the reimbursement of the 
national health insurance in Japan. Orbital exenteration was 
initially indicated for the local control of malignancy as the 
standard of care in this patient. However, the patient and her 
family wished to avoid radical surgery and the clinicians, also 
wished to search for the other options because of the patient's 
advanced age. Proton beam therapy was thus chosen as the 
first‑line treatment for unresectable melanoma in the head and 
neck according to the rule of the national health insurance 
in Japan (16‑18). The patient had satisfactory outcome and 
regained better quality of life: She had covered the left‑side 
tumor with gauze eye patch for cosmetic reasons before the 
therapy while she could blink and close the eye with the eyelid 
on the left side after the therapy.
On the initial presentation, biopsy could only obtain super‑
ficial hemorrhage‑prone tissue of the tumor and pathological 
Figure 2. Images of the mass before and after proton beam therapy. 
(A) T1‑weighted magnetic resonance image at the initial visit in an 
80‑year‑old woman, showing lobulated ocular surface mass with contrast 
enhancement on the left side (arrowed). (B) Abnormal uptake in the area 
of the left eyelid (maximum standardized uptake value, SUVmax=14.04) in 
whole‑body 2‑[18F]fluoro‑2‑deoxy‑D‑glucose positron emission tomography 
at the initial visit. (C) CT scan, showing multiple metastatic nodules in 
bilateral lung fields one month after the conclusion of proton beam therapy, 
3.5 months from the initial visit. (D) CT scan at the same time, showing 
the reduced ocular surface mass with contrast enhancement (arrowed). 
CT, Computed tomography. 
Figure 3. (A) Biopsy specimen in hematoxylin‑eosin stain of the ocular sur‑
face mass at the initial visit. Note anomalous epithelioid cells (arrows) with 
melanin pigments which are dispersed in fibrin and hemorrhage. (B) The 
anomalous cells were positive for cocktail‑mix antibodies against tyrosinase, 
melanoma antigen recognized by T cells‑1 and human melanoma black‑45, 
indicative of malignant melanoma. Scale bar, 50 µm. 
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diagnosis was based on immunocytochemical examinations. 
Following the proton beam therapy, excisional biopsy of the 
residual eyelid lesion was done again to confirm the patho‑
logical diagnosis of malignant melanoma and also to examine 
BRAF mutations in the melanoma tissue. Around the same 
time, the patient was found to have multiple metastatic lesions 
in bilateral lung fields. According to the standard protocol 
for unresectable and metastatic malignant melanoma (19,20), 
pembrolizumab was introduced, instead of the combination of 
MEK inhibitor and BRAF inhibitor, based on the absence of 
the BRAF mutation in the melanoma tissue. The sequence of 
events in this patient, namely, proton beam therapy for local 
control of unresectable conjunctival malignant melanoma, 
followed later by the administration of immune checkpoint 
inhibitors or the combination of MEK inhibitor and BRAF 
inhibitor, could become the standard of care in the modern 
era. Indeed, in the present patient, pembrolizumab appeared 
to have an effect on the reduction of malignant melanoma in 
the original and metastatic lesions, but actual evaluation of the 
effect could not be accomplished since the patient suddenly 
succumbed.
The patient was reported to have succumbed suddenly 
to unknown causes by the emergency transportation to a 
local hospital. The patient had hypothyroidism, probably 
induced by the administration of pembrolizumab, and thus 
was taking oral thyroid hormone. Autoimmune diseases, 
such as thyroiditis, pneumonitis and uveitis, should be 
kept in mind in patients who receive immune checkpoint 
inhibitors (21). The sudden mortality might be attributed 
to possible carditis or pneumonitis as a manifestation of 
pembrolizumab‑induced autoimmune diseases, but the exact 
situation was not confirmed clinically in the patient. Until 
the sudden mortality, the patient was healthy and had normal 
activities of daily life.
A major limitation in this case report is that the patient's 
presentation was unusual and that the sequence of event was 
thus out of the standard. First, only the surface biopsy could 
be done in the large protruding hemorrhage‑prone melanoma 
instead of standard resection. Secondly, proton beam therapy 
was chosen as the first‑line treatment for this giant conjunc‑
tival melanoma. The aim of therapeutic strategy at the initial 
presentation was to enhance the quality of life in this aged 
woman and the corneal melt as a sequel to proton beam 
therapy was anticipated in advance. On the initial phase 
of the patient's presentation, it was planned to use immune 
checkpoint inhibitors or molecular target drugs as an adjunct 
therapy since distant metastases to lung or liver would be 
unavoidable at the stage of the disease. In this context, it was 
not expected the complete response to proton beam therapy 
alone and residual melanoma lesions in the eyelid skin could 
be used as the biopsy site for examining the BRAF mutation 
to determine the appropriate adjunct therapy. It should be 
emphasized that the present case would not be recognized 
as the standard for local control of conjunctival melanoma at 
the current time.
In conclusion, proton beam therapy could be placed as a 
treatment option for local control of unresectable conjunctival 
malignant melanoma. Proton beam therapy as the first‑line 
treatment, followed by adjunct therapy with immune check‑
point inhibitors, could become the standard of care in near 
future for unresectable giant conjunctival melanoma. This 
conclusion, based on a single patient, naturally has a limitation 
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